MAGE-A3 and NY-ESO-1 Immunotherapy

Published: Oct 15, 2008 8:00 am
Brand Name:
Generic Name:
Code Name: MAGE-A3 and NY-ESO-1
Company: University of Arkansas
FDA Clinical Phase: 2/3

Description:

The purpose of MAGE-A3 and NY-ESO-1 immunotherapy is to generate anti-myeloma T-cells (natural immune system cells) to kill myeloma cells and nothing else.

Clinical Trials:
For a list of clinical trials studying MAGE-A3 and NY-ESO-1 immunotherapy for the treatment of multiple myeloma, see ClinicalTrials.gov.

Source: ClinicalTrials.gov, Multiple Myeloma AND MAGE-A3, http://www.clinicaltrial.gov/ct2/show/NCT00090493?term=multiple+myeloma+AND+MAGE-A3&rank=1 (as of September 4, 2008)

Related Articles: